Comparative antibacterial activity of the new oral cephalosporin BMY-28100.
The in vitro activity of BMY-28100 was compared with that of four other oral cephalosporins against gram-positive cocci, Branhamella catarrhalis and Haemophilus influenzae. BMY-28100 showed 5-20 times better activity against staphylococci and streptococci. Methicillin-resistant staphylococci and enterococci were resistant to the drug. Branhamella catarrhalis and Haemophilus influenzae strains were moderately susceptible. Time-kill curve studies showed BMY-28100 to be equally as active as benzylpenicillin, amoxycillin, flucloxacillin and cefaclor. By virtue of its in vitro spectrum, BMY-28100 can be considered a potentially useful agent for treatment of respiratory tract infections.
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002511:Cephalosporins / Q000494:pharmacology*; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D006193:Haemophilus influenzae / Q000187:drug effects*; D008826:Microbial Sensitivity Tests; D009016:Moraxella / Q000187:drug effects*; D013210:Staphylococcus / Q000187:drug effects; D013291:Streptococcus / Q000187:drug effects; D000097670:Cefprozil
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D000097670:Cefprozil